Cumberland Advisors Inc. grew its position in SPDR S&P Biotech (NYSEARCA:XBI) by 227.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 185,419 shares of the exchange traded fund’s stock after acquiring an additional 128,779 shares during the quarter. SPDR S&P Biotech accounts for about 4.8% of Cumberland Advisors Inc.’s holdings, making the stock its 7th largest position. Cumberland Advisors Inc.’s holdings in SPDR S&P Biotech were worth $13,304,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Howard Capital Management lifted its position in shares of SPDR S&P Biotech by 2.5% in the 3rd quarter. Howard Capital Management now owns 154,827 shares of the exchange traded fund’s stock worth $14,843,000 after acquiring an additional 3,780 shares during the period. Rafferty Asset Management LLC lifted its position in shares of SPDR S&P Biotech by 114.1% in the 3rd quarter. Rafferty Asset Management LLC now owns 941,464 shares of the exchange traded fund’s stock worth $90,258,000 after acquiring an additional 501,695 shares during the period. Wexford Capital LP bought a new stake in shares of SPDR S&P Biotech in the 3rd quarter worth approximately $3,381,000. Natixis lifted its position in shares of SPDR S&P Biotech by 5.5% in the 2nd quarter. Natixis now owns 49,498 shares of the exchange traded fund’s stock worth $4,712,000 after acquiring an additional 2,594 shares during the period. Finally, Adirondack Trust Co. lifted its position in shares of SPDR S&P Biotech by 73.6% in the 3rd quarter. Adirondack Trust Co. now owns 5,895 shares of the exchange traded fund’s stock worth $565,000 after acquiring an additional 2,500 shares during the period.
Get SPDR S&P Biotech alerts: Shares of XBI stock traded up $0.98 during mid-day trading on Tuesday, reaching $80.48. The stock had a trading volume of 6,088,529 shares, compared to its average volume of 7,459,346. SPDR S&P Biotech has a one year low of $64.38 and a one year high of $101.55.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 27th. Shareholders of record on Monday, December 24th were given a $0.012 dividend. The ex-dividend date was Friday, December 21st. This represents a $0.05 dividend on an annualized basis and a dividend yield of 0.06%.
TRADEMARK VIOLATION WARNING: “Cumberland Advisors Inc. Has $13.30 Million Holdings in SPDR S&P Biotech (XBI)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2019/01/08/cumberland-advisors-inc-has-13-30-million-holdings-in-spdr-sp-biotech-xbi.html. SPDR S&P Biotech Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Article: Catch-Up Contributions
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).
